TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $208,542 | -86.4% | 13,577 | -81.3% | 0.00% | -100.0% |
| Q4 2022 | $1,529,785 | -41.9% | 72,743 | -31.9% | 0.00% | -33.3% |
| Q3 2022 | $2,633,000 | +120.2% | 106,865 | +116.4% | 0.00% | +200.0% |
| Q2 2022 | $1,196,000 | +260.2% | 49,374 | +116.9% | 0.00% | – |
| Q2 2021 | $332,000 | -88.2% | 22,761 | -79.8% | 0.00% | -100.0% |
| Q1 2021 | $2,818,000 | +127.6% | 112,848 | +148.4% | 0.00% | +50.0% |
| Q4 2020 | $1,238,000 | – | 45,424 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |